Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
The Japan Pharmaceutical Manufacturers Association (JPMA) is moving to overhaul its organizational structure as it seeks to acquire a legal corporate status, aiming to strengthen its ability to respond more quickly to increasingly complex domestic and global challenges. The JPMA…
To read the full story
Related Article
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
April 21, 2026
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
- JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
April 2, 2026
ORGANIZATION
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
- LINK-J Eyes Stronger Ties with AI, Semiconductor Sectors
September 2, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…